Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Buprenorphine plays a major role in advanced healthcare as it is used in acute pain management, chronic pain management and in treatment of opioid addiction. It is synthetic phenanthrene with narcotic analgesic activity.

The global buprenorphine market is estimated to be valued at US$ 3,681.9 million in 2020 and is expected to exhibit a CAGR of 14.5% during the forecast period (2020-2027).

Figure 1. Global Buprenorphine Market Value (US$ Mn), by Region, 2020

Buprenorphine  | Coherent Market Insights

The increasing prevalence of chronic pain is expected to propel growth of the global buprenorphine market

Buprenorphine is an opioid which is used in treatment of acute pain management and chronic pain management in patients undergoing treatment of cancer, multiple sclerosis or other life threatening diseases. Moreover, high prevalence of cancer is expected to propel demand for cancer therapies which is expected to drive the market growth. According to Cancer Research UK, factsheet around 17 million people were diagnosed with cancer in 2018.

Moreover, the increasing incidence of multiple sclerosis is expected to propel growth of the global buprenorphine market during the forecast period. According to the Multiple Sclerosis Trust, 2018, an estimated 2,500,000 cases of multiple sclerosis are diagnosed globally.

However, side effects such as opioid withdrawal symptoms such as diarrhea and risk of fatal overdose from respiratory failure and drug dependency are expected to hamper the market growth. Also, buprenorphine is available in sublingual/buccal tablets and film formulations which is less convenient than oral route of administration, and supervised treatment can be part of patients care, e.g. for patients who receive treatment in methadone clinics, which is particularly common in Europe region, thus limiting patients' access and hindering the market growth.

Figure 2. Global Buprenorphine Market Share (%), by Application, 2020

Buprenorphine  | Coherent Market Insights

Increasing opioid abuse in North America is expected to boost the market growth.

North America holds dominant position in the global buprenorphine market owing to high prevalence of opioid and heroin abuse. According to the Substance Abuse and Mental Health Services Administration (SAMSHA) under the U.S. Department of Health and Human Services, an estimated 11.4 million people misused opioids prescription in 2016. Moreover, an estimated 13,219 heroin deaths occurred in 2016 was increased to 15,594 in 2017.

Moreover, an increase in the geriatric population is expected to propel demand for osteoarthritis cases, which is expected to drive the market growth during the forecast period. According to the Rheumatoid Arthritis. Org Facts, in October 2018, around 1.3 million Americans and around 1% of the world population is affected by rheumatoid arthritis, which is a third major form of osteoarthritis and gout.

request-sample

Buprenorphine Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 3,681.9 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 14.5% 2027 Value Projection: US$ 10,898.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Application: Analgesic, Opioid Antagonist.
  • By Route of Administration: Injectables, Sublingual, Transdermal Patches.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co.

Growth Drivers:
  • Rising prevalence of chronic pain
  • High prevalence of opioid and heroin abuse
  • Rising geriatric population prone to painful disease conditions such as osteoarthritis
Restraints & Challenges:
  • Side effects such as opioid withdrawal symptoms causing diarrhea
  • Drug dependency

Global Buprenorphine Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector.

Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global Buprenorphine drugs market during the forecast period.

However, the COVID-19 infection can affect the bones and joints causing pain which is expected to drive growth of the global Buprenorphine market during the forecast period. According to the Journal of Clinical Orthopedics and trauma, in May 2020, the coronavirus affects bones and joints of affected patients. As a result, several orthopedic doctors have been deployed for monitoring patients suffering from coronavirus infection. In order to treat such patients, there has been an increase in the manufacture of drugs and research and development of advanced solutions.

Key Players

Major players operating in the global buprenorphine market are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co.

Buprenorphine is a synthetic opioid alkaloid thiamine derivative with around 25- 40 times more potency than morphine. It acts primarily on the central nervous system and indicated for treatment of moderate to severe pain, peri-operative analgesia and opioid dependence. It is marketed in various dosage forms such as injectables, sublingual tablets & spray, transdermal patches.

Market Dynamics

Increasing prevalence of chronic pain, trauma injuries is a major factor driving buprenorphine market growth. According to the National Health Interview Survey (NHIS) 2016, an estimated 50 million of the U.S. adults suffered with chronic pain and around 19.6 million has high impact of chronic pain. Moreover, government initiatives for combatting problem of substance dependency and drug abuse is expected to boost the market growth. For instance, in April 2013, the Republic of Philippines under the President Rodrigo Roa Duterte, designed anti-drug cleansing efforts in cooperation with government and non-government agencies.

However, lack of licensed physicians for prescribing buprenorphine can hinder the market growth. According to the American Journal of Preventive Medicine, in June 2018, less than 4% licensed physicians were approved to prescribe buprenorphine for opioid use disorder.

Key features of the study:

  • This report provides in-depth analysis of the global buprenorphine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global buprenorphine market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global buprenorphine market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global buprenorphine market.

Detailed Segmentation:

  • Global Buprenorphine Market, By Application:
    • Analgesic
    • Opioid Antagonist
  • Global Buprenorphine Market, By Route of Administration:
    • Injectables
    • Sublingual
    • Transdermal Patches
  • Global Buprenorphine Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Buprenorphine Market, By Region:
    • North America
      • By Application:
        • Analgesic
        • Opioid Antagonist
      • By Route of Administration
        • Injectables
        • Sublingual
        • Transdermal Patches
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Application:
        • Analgesic
        • Opioid Antagonist
      • By Route of Administration
        • Injectables
        • Sublingual
        • Transdermal Patches
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Application:
        • Analgesic
        • Opioid Antagonist
      • By Route of Administration
        • Injectables
        • Sublingual
        • Transdermal Patches
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Application:
        • Analgesic
        • Opioid Antagonist
      • By Route of Administration
        • Injectables
        • Sublingual
        • Transdermal Patches
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Application:
        • Analgesic
        • Opioid Antagonist
      • By Route of Administration
        • Injectables
        • Sublingual
        • Transdermal Patches
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Application:
        • Analgesic
        • Opioid Antagonist
      • By Route of Administration
        • Injectables
        • Sublingual
        • Transdermal Patches
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Siegfried*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Sanofi
    • Johnson Matthey
    • Mallinckrodt
    • Noramco
    • Unichem Laboratories
    • Arevipharma GmbH
    • Resonance-labs
    • Sun Pharmaceutical Industries Ltd.
    • Rusan Pharma
    • Micro Orgo Chem
    • Faran Shimi Pharmaceutical Co.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Application
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Buprenorphine Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Market Scenario
    • Impact of COVID-19 Market on the Buprenorphine Products
  5. Global Buprenorphine Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Analgesic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Opioid Antagonist
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Buprenorphine Market, By Route of Administration, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Injectables
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Sublingual
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Transdermal Patches
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Buprenorphine Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Buprenorphine Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Siegfried
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson Matthey
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mallinckrodt
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Noramco
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Unichem Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Arevipharma GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Resonance-labs
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Rusan Pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Micro Orgo Chem
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Faran Shimi Pharmaceutical Co.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 23 figures on "Buprenorphine Market” - Global forecast to 2027

Frequently Asked Questions

The global buprenorphine market size is estimated to be valued at US$ 3,681.9 million in 2020 and is expected to exhibit a CAGR of 14.5% between 2020 and 2027.
The rising prevalence of chronic pain, opioid and heroin abuse, and the rising geriatric population prone to painful disease conditions such as osteoarthritis are favoring the market growth.
The opioid antagonist segment is expected to be the leading application segment in the global buprenorphine market during the forecast period (2020-2027).
North America buprenorphine market is expected to generate highest revenue share during the forecast period.
Major players operating in the global buprenorphine market are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co.
Side effects such as opioid withdrawal symptoms causing diarrhea and Drug dependency are the key factors hampering the growth of the global buprenorphine market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner